Literature DB >> 7773729

Evidence that meizothrombin is an intermediate product in the clotting of whole blood.

E G Bovill1, R P Tracy, T E Hayes, R J Jenny, F H Bhushan, K G Mann.   

Abstract

Meizothrombin is an intermediate that is produced during the conversion of prothrombin to thrombin in systems composed of purified factor Xa and factor Va that are quantitatively assembled on an anionic phospholipid surface. The biological significance of this intermediate has recently been challenged by the apparent absence of meizothrombin during clotting of sodium citrate-anticoagulated plasma. We analyzed the formation of thrombin during coagulation of nonanticoagulated, unchilled, minimally manipulated whole blood in glass tubes. The process was stopped at 0, 3, 5, and 7 minutes by the addition of biotinylated peptidyl chloromethyl-ketone active-site labeling reagents. Plasma/serum was separated by centrifugation, and labeled species were extracted by immunoadsorption with a polyclonal anti-prothrombin antibody. The purified prothrombin-derived species were separated by SDS-polyacrylamide gradient gel electrophoresis and visualized on a chemiluminescent avidin blot. Meizothrombin appeared as an intermediate product of this reaction and persisted with some increase through the 7-minute time point. We also observed incorporation of the active-site label into a species of lower molecular weight consistent with the B1 chain of beta- and/or gamma-thrombin. These degraded forms of thrombin have not been previously demonstrated in a biologically relevant preparation. Our data clearly establish the generation of meizothrombin as an intermediate product of thrombin generation during whole-blood clotting. The data also represent the first experimental evidence for the generation of beta- and gamma-thrombin in a biologically relevant environment and time scale.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7773729     DOI: 10.1161/01.atv.15.6.754

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  10 in total

1.  Dilutional control of prothrombin activation at physiologically relevant shear rates.

Authors:  Laura M Haynes; Yves C Dubief; Thomas Orfeo; Kenneth G Mann
Journal:  Biophys J       Date:  2011-02-02       Impact factor: 4.033

2.  Prothrombin activation in blood coagulation: the erythrocyte contribution to thrombin generation.

Authors:  Matthew F Whelihan; Vicentios Zachary; Thomas Orfeo; Kenneth G Mann
Journal:  Blood       Date:  2012-09-11       Impact factor: 22.113

3.  Prothrombin activation on the activated platelet surface optimizes expression of procoagulant activity.

Authors:  Jeremy P Wood; Jay R Silveira; Nicole M Maille; Laura M Haynes; Paula B Tracy
Journal:  Blood       Date:  2010-12-03       Impact factor: 22.113

4.  Activation of factor XI by products of prothrombin activation.

Authors:  Anton Matafonov; Suryakala Sarilla; Mao-fu Sun; John P Sheehan; Vladimir Serebrov; Ingrid M Verhamme; David Gailani
Journal:  Blood       Date:  2011-04-28       Impact factor: 22.113

5.  Hemolysis exacerbates hyperfibrinolysis, whereas platelolysis shuts down fibrinolysis: evolving concepts of the spectrum of fibrinolysis in response to severe injury.

Authors:  Hunter B Moore; Ernest E Moore; Eduardo Gonzalez; Kirk C Hansen; Monika Dzieciatkowska; Michael P Chapman; Angela Sauaia; Bernadette West; Anirban Banerjee; Christopher C Silliman
Journal:  Shock       Date:  2015-01       Impact factor: 3.454

6.  Membrane binding by prothrombin mediates its constrained presentation to prothrombinase for cleavage.

Authors:  Harlan N Bradford; Steven J Orcutt; Sriram Krishnaswamy
Journal:  J Biol Chem       Date:  2013-08-12       Impact factor: 5.157

7.  Eisenia fetida protease-III-1 functions in both fibrinolysis and fibrogenesis.

Authors:  Jing Zhao; Rong Pan; Jian He; Ying Liu; Dong-Feng Li; Rong-Qiao He
Journal:  J Biomed Biotechnol       Date:  2007

8.  MASP-1 Induced Clotting--The First Model of Prothrombin Activation by MASP-1.

Authors:  Lorenz Jenny; József Dobó; Péter Gál; Verena Schroeder
Journal:  PLoS One       Date:  2015-12-08       Impact factor: 3.240

9.  Snake Venom Cytotoxins, Phospholipase A2s, and Zn2+-dependent Metalloproteinases: Mechanisms of Action and Pharmacological Relevance.

Authors:  Sardar E Gasanov; Ruben K Dagda; Eppie D Rael
Journal:  J Clin Toxicol       Date:  2014-01-25

10.  Structural transitions during prothrombin activation: On the importance of fragment 2.

Authors:  Ty E Adams; James A Huntington
Journal:  Biochimie       Date:  2015-09-10       Impact factor: 4.079

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.